<DOC>
	<DOCNO>NCT01592253</DOCNO>
	<brief_summary>For patient meet inclusion criterion agree participate study , investigator sample peripheral blood 10cc perform analysis immunologic profile conversion immune suppressant . At 1 month , 6 month , 1 year conversion Immune suppressant ( CNI rapamune ) , investigator perform tha analysis fo immune profile . During study period , interval visit subclinic kind laboratory test ( Blood urine test ) would change compare start study .</brief_summary>
	<brief_title>Study Evaluate Safety Immunologic Biomarker Rapamune Patients With Stable Renal Transplant Recipient</brief_title>
	<detailed_description />
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Renal transplant recipient pass least 10 year 2 . No acute rejection episode previous 6 month 3 . No change prescription immune suppressant 4 . Normal allograft function ( MDRD eGFR &gt; 80 mL/min/1.73 m2 ) 5 . Change allograft function le 10 % baseline value durant previous 1 year 6 . No proteinuria hematuria 1 . Patients donut want participate study 2 . Patients continue immune suppressant due another cause ( e/g combine autoimmune disease )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>